GlassScriptPhysician profile
Sara Sarwar Riaz
NPI 1215192729
$1,577.32
in general payments reported to CMS, 2019-2025
32 companies · $39.49 in 2025
The $39.49 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $124 · 2021: $22.99 · 2023: $337 · 2024: $401 · 2025: $39.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762 · Education: $15.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.98 |
| Education | $15.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $227.40 | 2023-2024 | Imfinzi, Calquence, Tagrisso |
| Novartis Pharmaceuticals Corporation | $186.20 | 2019-2024 | |
| Amgen INC. | $177.79 | 2019-2023 | Xgeva, Nplate, Vectibix |
| E.R. Squibb & Sons, L.L.C. | $174.28 | 2019-2023 | Opdivo |
| Merck Sharp & Dohme LLC | $62.30 | 2019 | |
| Lilly USA, LLC | $62.23 | 2019-2024 | Verzenio |
| Jazz Pharmaceuticals INC. | $62.14 | 2019-2024 | |
| Genentech USA, INC. | $53.15 | 2019-2025 | Polivy |
| Pfizer INC. | $44.50 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.83 | 2019 | |
| Celgene Corporation | $40.12 | 2019-2023 | Reblozyl |
| Beigene USA, INC. | $33.59 | 2023 | Brukinsa |
| Emmaus Medical, INC. | $33.23 | 2024 | Endari |
| Sobi, INC | $32.01 | 2024-2025 | |
| Genzyme Corporation | $31.38 | 2019-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acrotech Biopharma INC. | $28.34 | 2024 | Beleodaq |
| Gilead Sciences, INC. | $27.18 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.79 | 2019 | |
| Blueprint Medicines Corporation | $22.11 | 2024 | Ayvakit |
| Pharmacyclics LLC, An Abbvie Company | $21.49 | 2023 | Imbruvica |
| Teva Pharmaceuticals USA, INC. | $19.58 | 2019 | |
| Mirati Therapeutics, INC. | $19.22 | 2023 | Krazati |
| Pharmacosmos Therapeutics INC. | $18.71 | 2024 | Monoferric |
| Exelixis INC. | $18.29 | 2019 | |
| Shire North American Group INC | $17.43 | 2019 | |
| Myriad Genetic Laboratories, INC. | $16.65 | 2024 | Myrisk |
| Array Biopharma INC | $16.49 | 2019 | |
| Taiho Oncology, INC. | $14.83 | 2019 | |
| Janssen Biotech, INC. | $13.16 | 2020 | |
| Daiichi Sankyo INC. | $12.96 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.81 | 2019 | |
| Puma Biotechnology, INC. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Sarwar Riaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.